Gt Biopharma, Inc. · NASDAQ:GTBP
Gt Biopharma — Investor Presentation (January 2025)
25 slides from Gt Biopharma's investor presentation, Jan 27, 2025
Slide 1: GT Biopharma Corporate Presentation — January 2025
GT BIOPHARMA Tri-Specific NK Cell ENGAGERS (TriKE®) Targeted NK Cell Therapies to Treat Cancer and Autoimmune Disease GT Biopharma (Nasdaq: GTBP) Corporate Presentation — January 2025
Slide 2: Disclaimer
Disclaimer GT BIoPHARMA This presentation may not be reproduced, redistributed, published or passed on to any other persons, directly or indirectly, in whole or in part, for any purpose. This presentation is not directed to, intended for distribution to, or to be used by any person or entity that is
Slide 3: Investment Opportunity — Next Generation of NK Cell ENGAGERS
Investment Opportunity — Next Generation of NK Cell ENGAGERS Ger BIpeHARNnA Proprietary TriKE® Platform - Camelid Nanobodies TriKE® are tri-specific NK cell ENGAGERS Incorporate Camelid “nanobodies” + Protein therapeutics to harness the natural killing power of NK cells with - NOT NK cell therapy +
Slide 4: TriKE® Pipeline
TriKE® Pipeline GT BioPpHARMA TriKE® Product IND-Enabling/ Candidates Approach Target Indication Pre-Clinical GMP Manufacturing Phase 1 Phase 2 T Leukemia — AML, Monotherapy CD33 " GTB-3650 Phase 1 trial cre.aeso MDs i a x rT dosed on 01/21/2025 Camelid Combination Leukemia - AML, with CD33 MDS Chem
Slide 5: Natural Killer Cell ENGAGERS to Fight Cancer
Natural Killer Cell ENGAGERS to Fight Cancer Per vomnn Natural Killer Cells * Cytotoxic lymphocytes in the innate immune system * Recognize and kill cancer cells * Mediate antibody-dependent cellular cytotoxicity (ADCC) via the highly potent CD16 activating receptor NK Cell ENGAGERS * TriKE® nanobod
Slide 6: TriKE®: Tri-Specific NK Cell ENGAGERS - A Modular Platform
TriKE®: Tri-Specific Natural Killer (NK) Cell ENGAGERS - A Modular Platform Ger BIOPHARMA Proprietary platform utilizing camelid nanobody technology designed to bridge NK cells to tumor cells while inducing NK cell activation and expansion at the site of the tumor to enhance killing Tri-specific Mod
Slide 7: TriKE® Modular Platform Allows for Multiple Tumor-Associated Antigen
TriKE® Modular Platform Allows for Multiple Tumor-Associated Antigen Ger BIOPHARMA Hematological CD22 or BCMA ss > Malignancies scFv Nanobody CLEC128 5; @—= Myeloid Cell 6 = Anti-Tumor Associated Antigen aie Ss Be col » ¢ Binds to well-known tumor-specific antigens B7H3 ‘Pan Tumor & MM * Defines the
Slide 8: TriKE® — NK Cell-Driven Serial Killing of AML Tumor Cells
TriKE® — NK Cell-Driven Serial Killing of AML Tumor Cells ber sone First-in-class modular immune oncology protein therapeutic platform technology — not a cell therapy Target-directed antibody-dependent cellular cytotoxicity (ADCC) killing Integrated CD16 and IL-15 driven activation of NK cells: « AD
Slide 9: GTB-3550 Phase 1 Demonstrates Proof of Concept for CD33 TriKE® in AML/MDS
GTB-3550 Phase 1 Demonstrates Proof of Concept for CD33 TriKE® in AML/MDS Ger BIOPHARMA GTB-3550 induces reproducible NK cell proliferation, activation and persistence in all patients at all dose levels with minimal clinically significant toxicity Minimal CRS resulting from hyperactivation of patien
Slide 10: GTB 3650 for AML and MDS; GTB 5550 for Solid Tumors
GT BIOPHARMA GTB 3650 for AML and MDS GTB 5550 for Solid Tumors Second generation TriKEs® utilize camelid nanobody technology
Slide 11: Advantages of Camelid Antibodies - Nanobodies in 2nd Generation TriKEs®
Advantages of Camelid Antibodies - Nanobodies in 2nd Generation TriKEs® ber BIOPHARMA + Camelidae family of mammals include llamas, camels, and alpacas + Camelid antibody is made up of only 2 heavy chains Heavy chain IgG (hclgG) VyH Do not contain the CH1 region Retain an antigen binding domain — V,
Slide 12: Our Approach — Co-Stimulation of CD16 and IL-15
Our Approach — Co-Stimulation of CD16 and IL-15 Ger BIOPHARMA TriKE® Competitive Differentiation | NKp46/cD16| |cp16A| | NKG2D/CD16 | I peed cia) The anti-CD16 component of the TriKE® binds FcRylll with affi ‘| high affinity innate pharma med Dragonfly |i ~_ | THERAPEUTICS + TriKE® does not result i
Slide 13: GTB 7550 for Autoimmune Disease
GT BIOPHARMA GTB 7550 for Autoimmune Disease Targeting CD19 for B-Cell Depletion In Vivo 13
Slide 14: GTB 7550 for Autoimmune Disease
GTB 7550 for Autoimmune Disease Geroomann + GTB-7550 TriKE® product candidate is in development for the treatment of lupus and other autoimmune disorders + GTB-7550 TriKE® is a tri-specific molecule composed of a camelid nanobody that binds the CD16 receptor on NK cells, a scFv ENGAGER against CD19
Slide 15: GTB 7550 for Autoimmune Disease — CD19-targeted TriKE in CLL
GT BioPpHARMA GTB 7550 for Autoimmune Disease © blood advances: REGULAR ARTICLE Novel CD19-targeted TriKE restores NK cell function and proliferative .“ capacity in CLL 161519 ‘NK cal profferation Martin Felices," Behiye Kodal,' Peter Hinderlie,’ Michael F. Kaminski,’ Sarah Cooley,’ Daniel J. Weisdo
Slide 16: Investment Opportunity — Next Generation of NK Cell ENGAGERS
Investment Opportunity — Next Generation of NK Cell ENGAGERS Ger BIpeHARNnA Proprietary TriKE® Platform - Camelid Nanobodies TriKE® are tri-specific NK cell ENGAGERS Incorporate Camelid “nanobodies” + Protein therapeutics to harness the natural killing power of NK cells with - NOT NK cell therapy +
Slide 17: Contact Us
Contact U S Ger BIOPHARMA GT BIOPHARMA Michael Breen, Exec. Chairman & Interim CEO Investor Relations Contact: Alan Urban, CFO Corey Davis, Ph.D. GT Biopharma, Inc. LifeSci Advisors 315 Montgomery Street, 10th Floor cdavis @lifesciadvisors.com San Francisco, CA 94104 212-915-2577 ir@gtbiopharma.com
Slide 18: Appendix
GT BIOPHARMA APPENDIX
Slide 19: Experienced Team With Deep Immuno-Oncology Experience
Experienced Team With Deep Immuno-Oncology Experience BNP PARIBAS Research Solutions i INSINGER “BEAUFORT CLYDE&CO infotrieve REACHLOCAL Jeffrey Miller, MD Martin Felices, PhD sulting Senior Consulting Scientist UNIVERSITY UNIVERSITY OF MINNESOTA OF MINNESOTA The University of Minnesota, pursuant to
Slide 20: Recent M&A and BD Deals Highlight Value of NK Cell Engagers
Recent M&A and BD Deals Highlight Value of NK Cell ENGARERS and Immuno-Oncology milestones 20% royalties Innovator @aFeeimep @aeeimeD Pawunis &3 Dragonfly nate pharma . - eo eo Acquirer SANOFI. ROIVANT, SANOFI 9 @g GILEAD | SANOFI. Date 8/27/2018 11/9/2020 12/21/2021 5/2/2022 12/19/22 Deal Type Lice
Slide 21: GTB-3550 AML/MDS Phase 1 Study Design
GT BioPpHARMA GTB-3550 AML/MDS Phase 1 Study Design Sygikgiday —_(n=2) ( Dose Level 3: ngikgiday _(! ( Dose Li 100 ugikg/day (1 2) n=2) SOpgikg/day (n=2) (n=2) 150 pgikg/day _(n=2) GTB-3550 TrKE CI #1 GTB-3550 TrKE C1 #2 | | | | | > GTB-3550 THKE Cl #3 Re-assessment [ Block 1 | 3-day rest Block 2 |
Slide 22: GTB-3550 Activation of Endogenous NK Cells
GTB-3550 Activation of Endogenous NK Cells Gerscmnn Panel A: Increase in NK cell activation upon administration of GTB-3550 Panel B: Increase in absolute number of NK cells during treatment (n= 2 patients per dose) (n= 2 patients per dose) 1004 12000 © Susie so000] © 9 ¥0K9 4 10.ugikg soo] 10u9k9 oi
Slide 23: GTB-3550 First in Human Phase 1 Clinical Trial — Individual Results
GTB-3550 First in Human Phase 1 Clinical Trial — Individual Results Basar Disease and Prior Treatment History (ugikgia) Disease Characteristics Before GTB-3550 Therapy Disease Characteristics After GTB-3550 Therapy GT BioPpHARMA Response Post Cycle 1 rir AML. Triple Hit Lymphoma - 6 therapies: 1. R-
Slide 24: Selected Financial Information
Selected Financial Information Cash + Short Term Investments $ 6,511,000 $ 13,972,000 Other Assets 248,000 137,000 Total Assets 6,759,000 14,109,000 Accounts Payable + Accrued Expenses $ 4,480,000 $ 5,523,000 Other Liabilities - 58,000 Warrant Liability 182,000 1,052,000 Total Liabilities 4,662,000
Slide 25: Capitalization Table
Capitalization Table Grams Stock O 2,234,328 Legacy Warrants 291,629 sso 8% 2024 Warrants 828,800 $4.47 24% Stock Options 124,600 $32.69 4% Fully Diluted Shares 3,479,375 100% Cytovance Biologics, Inc. 219,457 Common Stock 9.8% Robert A. Marzilli 200,000 Common Stock 8.9% 25